TB-500 vs GHK-Cu: A Research Comparison
Quick Summary
TB-500 and GHK-Cu are two of the most-studied tissue-repair research peptides. TB-500 is the active C-terminal fragment of Thymosin β4, an actin-binding protein with established cell-migration mechanisms. GHK-Cu is a copper-binding tripeptide with broad transcriptional-modulation activity. Researchers contrast them to choose between an actin-cytoskeleton mechanism family (TB-500) and a transcriptional-program / metallopeptide mechanism family (GHK-Cu).
TB-500
Overview TB-500 (also known as Fequesetide) is a synthetic heptapeptide corresponding to the N-acetylated amino acid sequence 17–23 of the naturally occurring protein Thymosin Beta-4 (Tβ4). Its sequence is Ac-LKKTETQ.[1][2] The parent molecule, Thymosin Beta-4, is a ubiquitous 43-amino acid...
GHK-Cu
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
TB-500 and GHK-Cu are both standard reference compounds in tissue-repair and regenerative-peptide research. The two molecules share extensive overlap in research applications — dermal repair, angiogenesis-adjacent endpoints, anti-fibrotic research models — but operate through entirely separate mechanism families.
TB-500 is the active C-terminal fragment of Thymosin β4 (Tβ4), a 43-amino-acid peptide best known as the principal G-actin-sequestering molecule in cells. The TB-500 fragment retains the actin-binding and cell-migration activity of full-length Tβ4 and is widely used in research as a smaller, more synthetically tractable tool compound.
GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) that chelates a Cu(II) ion. Its mechanism family is broad transcriptional modulation paired with copper-cofactor delivery to copper-dependent enzymes such as lysyl oxidase and superoxide dismutase.
This page contrasts the two compounds across structural design, mechanism family, primary research applications, common stack pairings, and the SKU sizes Pure U.S. Peptides supplies for in-vitro research.
Side-by-Side: TB-500 vs GHK-Cu
| Property | TB-500 | GHK-Cu |
|---|---|---|
| Compound class | Thymosin β4 active fragment (synthetic peptide) | Naturally occurring tripeptide-copper complex |
| Sequence | Active C-terminal fragment of Tβ4 (~17 aa region) | Gly-His-Lys + Cu(II) (3 aa + copper) |
| Reported half-life | Short plasma half-life; metabolized rapidly | Short plasma half-life; copper-bound complex regenerated in plasma |
| Primary mechanism family | G-actin sequestration, cell-migration dynamics, anti-fibrotic NF-κB modulation | Broad transcriptional modulation (4,000+ genes), copper-cofactor delivery, SOD / lysyl-oxidase support |
| Primary research applications | Dermal cell-migration assays, corneal repair, cardiac-tissue research, anti-fibrotic models, hair follicle research | Collagen synthesis, decorin production, antioxidant SOD research, hair follicle, broad transcriptional-program research |
| Common research stack pairings | BPC-157, GHK-Cu (in GLOW / KLOW blends) | BPC-157, TB-500, KPV (in GLOW / KLOW blends) |
| SKU sizes available | 2 mg, 5 mg, 10 mg vials | 50 mg, 100 mg vials |
| Indicative price range | $$ | $$ |
How the Two Peptides Differ Mechanistically
TB-500, derived from Thymosin β4, contains the central actin-binding domain of the parent protein. Its core mechanism is sequestration of monomeric G-actin, which buffers the intracellular G-actin pool and influences actin polymerization dynamics during cell migration, lamellipodia formation, and tissue-repair processes.[1][2] Published research also reports downstream effects on cell migration in dermal and corneal models, anti-fibrotic signaling via reduced TGF-β downstream activity, and modulation of the NF-κB pathway in inflammation-research models.[3] In endothelial-cell research, TB-500 / Tβ4 supports tube formation and is associated with angiogenic-research endpoints, though through actin-cytoskeleton mechanisms rather than direct VEGFR receptor agonism.
GHK-Cu binds Cu(II) in a distorted square-planar pyramid geometry. The copper-bound complex modulates expression of more than 4,000 human genes in published microarray research, with major effects on collagen and decorin synthesis programs, antioxidant SOD upregulation, TGF-β-superfamily modulation, DNA-repair-pathway activation, and stem-cell-attraction signaling.[4][5] The copper-cofactor-delivery role is central — GHK-Cu provides Cu(II) to lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defense), and other copper-dependent enzymes that act on tissue-repair endpoints.
The mechanistic point of difference is fundamental. TB-500 acts on the cytoskeleton — it is an actin-binding peptide whose downstream effects flow from actin-pool buffering and cell-migration dynamics. GHK-Cu acts on transcriptional programs and as a copper-cofactor delivery mechanism — its downstream effects flow from gene-expression changes and from supporting copper-dependent enzymes that operate on tissue-repair substrates.
Research Applications Compared
TB-500 is most-cited in research on dermal-repair models (cell-migration assays, wound-closure research), corneal-repair research (Tβ4 has substantial corneal-research literature), cardiac-tissue research (Tβ4 has been studied in cardiac-repair Phase 2 research, with TB-500 used as a tool compound in preclinical extensions), anti-fibrotic research models, and hair-follicle research (Tβ4 promotes follicular development in published research). The actin-binding mechanism makes TB-500 a particularly useful tool compound when cell-migration endpoints dominate the research design.
GHK-Cu is most-cited in dermal-research models focused on collagen synthesis and decorin production, anti-photoaging research, hair-follicle research (GHK-Cu has its own substantial follicle-enlargement literature), antioxidant-research models (SOD upregulation), DNA-repair-pathway research, and broad transcriptional-program research in aging-cell models. Topical research formats dominate the GHK-Cu literature.
The two compounds appear together frequently in research stacks, including the GLOW blend (GHK-Cu + BPC-157 + TB-500). Researchers studying combined cytoskeletal and transcriptional-program mechanisms layer the two molecules to engage both pathways simultaneously.
Choosing Between Them
When researchers choose TB-500
TB-500 is the preferred research compound when the experimental design centers on cell-migration endpoints, actin-cytoskeleton dynamics, anti-fibrotic signaling, or corneal- and cardiac-tissue research. It is also the standard tool compound for Thymosin β4 fragment research where a smaller, more synthetically tractable peptide is preferred over the full-length parent.
When researchers choose GHK-Cu
GHK-Cu is the preferred research compound when the design centers on transcriptional programs, copper-cofactor delivery, collagen and decorin synthesis, antioxidant SOD upregulation, hair-follicle research, or topical dermal-research formats. It is also the standard tool compound for copper-tripeptide and metallopeptide research.
Chemical Properties Comparison
| Property | TB-500 | GHK-Cu |
|---|---|---|
| Molecular Formula | C₃₈H₆₈N₁₀O₁₄ | C₁₄H₂₂CuN₆O₄ |
| Molecular Weight | 889.018 g/mol | ~401.9 Da |
| CAS Number | 885340-08-9 | 89030-95-5 |
| Amino Acid Sequence | — | — |
| PubMed Citations | 29 referenced | 24 referenced |
Explore Full Research Profiles
TB-500
Overview TB-500 (also known as Fequesetide) is a synthetic heptapeptide corresponding to the N-acetylated amino acid sequence 17–23 of the naturally occurring protein Thymosin Beta-4 (Tβ4). Its sequence is Ac-LKKTETQ.[1][2] The parent molecule, Thymosin Beta-4, is a ubiquitous 43-amino acid...
GHK-Cu
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
Frequently Asked Research Questions
How are TB-500 and GHK-Cu mechanistically different?
+
Which compound is more associated with corneal and cardiac research?
+
Which compound is more associated with collagen and skin research?
+
Can TB-500 and GHK-Cu be studied together?
+
What is the relationship between TB-500 and Thymosin β4?
+
Why is GHK-Cu blue-purple in solution?
+
What sizes does Pure U.S. Peptides supply?
+
PubMed Citations Referenced
- [1]Goldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. PMID: 16099219
- [2]Sosne G, et al. Thymosin beta 4 and the eye: I, II. Ann N Y Acad Sci. 2010;1194:97-107. PMID: 20536456
- [3]Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-9. PMID: 17320857
- [4]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- [5]Pickart L, et al. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PMID: 25101282
- [6]Smart N, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci. 2010;1194:97-104. PMID: 20536457
- [7]Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID: 20536454
- [8]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236731
- [9]Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:385-95. PMID: 17600293
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.
Educational Scope. The mechanisms, pathways, and research applications discussed on this page describe published in-vitro, ex-vivo, and animal-model literature. They do not constitute medical advice, recommendations, or guidance for in-human use. Cited PubMed references describe preclinical research findings only. Researchers should consult their institutional review processes and original literature before designing any research study using these compounds.